CVM
$12.04
Cel-Sci
($.67)
(5.27%)
CVM
Earnings Whisper ®
N/A
3rd Quarter June 2020
Consensus:  ($0.15)
Revenue:  $0.10 Mil
Wednesday
Aug 12
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CVM reports earnings?
Beat
Meet
Miss

Where is CVM's stock price going from here?
Up
Flat
Down
Stock chart of CVM
Analysts
Summary of analysts' recommendations for CVM
Score
Grade
Pivots
Resistance
$13.01
$12.80
$12.42

$12.21

Support
$11.83
$11.62
$11.24
Tweet
Growth
Description
CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (IL-2) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or cocktail of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies.
Peers
BiogenAmgenGilead SciencesNeurocrine BiosciencesSeattle GeneticsBluebird BioQiagen N.V.NovavaxRepligenBio-Techne